Evercore ISI Forecasts Strong Price Appreciation for Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its price objective boosted by stock analysts at Evercore ISI from $170.00 to $180.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the medical research company's stock. Evercore ISI's price objective would suggest a potential upside of 12.66% from the company's previous close.

CRL has been the topic of several other reports. Robert W. Baird upped their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their price objective for the company from $188.00 to $182.00 in a report on Friday, May 23rd. Barclays upped their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a report on Thursday, May 8th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a report on Wednesday, May 14th. Finally, Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $174.54.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded down $3.88 during midday trading on Wednesday, reaching $159.78. The company had a trading volume of 518,978 shares, compared to its average volume of 1,029,720. The company's 50 day moving average price is $144.04 and its 200 day moving average price is $152.01. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The stock has a market cap of $7.85 billion, a P/E ratio of -245.81, a P/E/G ratio of 5.38 and a beta of 1.49. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The company's revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.27 earnings per share. As a group, sell-side analysts anticipate that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president directly owned 19,513 shares in the company, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Rothschild Investment LLC increased its position in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares during the last quarter. Brooklyn Investment Group increased its position in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock worth $27,000 after purchasing an additional 86 shares during the last quarter. HM Payson & Co. bought a new position in shares of Charles River Laboratories International in the first quarter worth approximately $31,000. Optiver Holding B.V. bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $37,000. Finally, GeoWealth Management LLC grew its position in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after acquiring an additional 190 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).